P-119 Impact of circulating tumor DNA on clinical decisions in the adjuvant setting in patients with colorectal cancer

Abstract

With the rise of molecular profiling, detection of minimal residual disease (MRD) has emerged as a tool for risk stratification in patients with early stage CRC with potential implications for adjuvant therapy. We sought to evaluate the clinical course of predominantly early-stage colorectal cancer (CRC) patients who underwent MRD assessment using the Signatera™ ctDNA assay and the impact this approach had on clinical decisions at West Cancer Center and Research Institute (WCCRI).